A regulatory approval could come within the next year for X4 Pharmaceuticals’ (Nasdaq: XFOR) lead oral CXCR4 antagonist, mavorixafor.
The US company, which is focused on the discovery and development of novel small-molecule therapeutics to benefit people with diseases of the immune system, has presented positive top-line results from a pivotal Phase III trial of the drug in WHIM syndrome, which refers to warts, hypogammaglobulinemia, infections and myelokathexis.
"Mavorixafor is the first and only oral investigational therapy to demonstrate durable improvements in severe chronic neutropenia and lymphopenia"
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze